Episode 52: 20 September 2021 Update and Questions Answered

Michael Frazis gives an update and answers questions.  0:26 – Introduction 1:10 – Performance update 1:58 – Comments on the NASDAQ100’s strong rally 2:46 – The performance of small-mid cap companies 3:38 – An analyse of where our returns have come from over the years 4:20 – Our past investment in bluebird bio 5:39 – Our IPO/pre-IPO investments in the life sciences 6:57 – We funded a PhD fellowship on research into Dystonia 8:45 – True customer love and explosive growth 9:14 – Our take on ESG and the rising coal prices 10:40 – The effects of currency fluctuations on a fund’s performance 12:23 – Drivers in the value of the AUD 13:36 – Comments on Opendoor and the three industries that are resistant to ecommerce 16:25 – Comments on Upstart 18:42 – Thoughts on the decline in digital health companies 20:03 – Question #1: What do you think of PointsBet? 21:31 – Question #2: Do we still hold Guardent and Dermtech? 23:30 – Question #3: The contribution of the life science companies to the fund’s performance 26:08 – Question #4: Are you planning on taking advantage of the current dip in the market? 26:23 – Question #5: What are the risk management strategies when if the market turns? 28:51 – Question #6: Customer love in the life sciences 29:09 – Question #7: How has the recent move back into China-tech progressed? 30:12 – Question #8: What do you think of developer tools ecosystem DevOps? 30:51 – Question #9: What is an odd stock that looks good at the moment? (Camplify and Cettire) 31:35 – Question #10: What are your thoughts on Megaport? 31:50 – Question #11: What are your thoughts on cloud in general? (Snowflake) 32:58 – Question #12: Do you see the fund’s China positions as trading or long-term holds? (Pinduoduo) 36:25 – Question #13: Would eye-wear replace mobiles? 37:20 – Question #14: What are your thoughts on the recent Canva valuation? 40:18 – Question #15: What are your thoughts on Fiverr?